{"groups":[{"description":"Treatment consists of 3 cycles of Doxorubicin hydrochloride IV (25 mg/m2) days 1 \\& 2, Vincristine sulfate IV (1.4 mg/m2 \\[max 2.8 mg\\]) Days 1 \\& 8, Prednisone orally (40 mg/m2) Days 1-7, Cyclophosphamide IV (600 mg/m2) Days 1 \\& 2, Filgrastim by mouth or IV (5 micrograms/kg/dose) 24 hours after Cyclophosphamide complete. See detailed description for remainder of therapy.\n\nradiation therapy: Undergo radiation therapy\n\ndoxorubicin hydrochloride: Given IV\n\nvincristine sulfate: Given IV\n\nprednisone: Given orally\n\ncyclophosphamide: Given IV\n\nifosfamide: Given IV\n\nvinorelbine tartrate: Given IV\n\ndexamethasone: Given IV\n\netoposide phosphate: Given IV\n\ncisplatin: Given IV\n\ncytarabine: Given IV\n\nfilgrastim: Given IV or subcutaneously","id":"FG000","title":"Doxorubicin, Vincristine, Cyclophosphamide and Filgrastim"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"62"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"9"}],"type":"Ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Protocol Violation"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"287"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"207"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"80"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}